文献速递耳科与耳神经

梅尼埃病的分子生物标志物:当前证据的范围综述

Molecular Biomarkers in Meniere's Disease: A Scoping Review of Current Evidence.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-08-17

该范围综述评估血液及内淋巴液中分子生物标志物对梅尼埃病(MD)的诊断与治疗价值。纳入21项研究,标志物分为结构性、调节性、免疫/氧化应激及杂类,部分显示鉴别诊断潜力,但方法异质性和缺乏重复验证限制临床应用。

要点

  • 结构性蛋白otolin-1和otoconin-90可能有助于鉴别MD与其他前庭疾病。
  • 调节性标志物(水通道蛋白-2、血管加压素相关肽)与内淋巴液异常相关。
  • 炎性细胞因子和氧化应激标志物反映疾病异质性,但证据尚需标准化验证。

核心结论

  • 分子生物标志物为MD的发病机制、诊断和治疗进展提供了重要见解。
  • 方法学变异和缺乏重复验证意味着正式临床应用前需标准化验证。

研究设计与样本

  • 遵循PRISMA指南的范围综述,由2名独立评审员进行筛选、数据提取和偏倚评估。
  • 检索OVID Medline、Ovid EMBASE、EBSCO CINAHL、Web of Science核心合集、ProQuest Dissertations和Cochrane Library。
  • 共纳入21项研究:病例对照71.4%、随机试验或综述14.4%、队列9.5%、病例系列4.8%。

主要发现

  • 分离的标志物分类:结构性24%、调节性24%、免疫/氧化应激38%、杂类14%。
  • 结构性蛋白(如otolin-1、otoconin-90)在区分MD与其他前庭疾病方面显示出潜力。
  • 调节性标志物(水通道蛋白-2、血管加压素相关肽)与液体异常相关。
  • 炎性细胞因子(TNF-α、IL-6、IL-1β)和氧化应激标志物(4-HNE)突显疾病异质性。
  • 维生素D、雌二醇及代谢组学改变提示激素和代谢变化。

临床怎么用

  • 当前证据尚不足以支持分子标志物常规用于MD的临床诊断或治疗决策。
  • 结构性蛋白等标志物未来可能辅助鉴别诊断,但需标准化检测和验证。

局限性

  • 方法学变异大且缺乏重复验证,阻碍了标志物的正式临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meniere's disease is a complex chronic inner ear condition that is characterized by vertigo, tinnitus, aural fullness, and progressive hearing loss. Currently, diagnostic strategies remain symptom-driven, and treatments focus on management of discrete episodes rather than targeting underlying pathophysiology. This review sets out to evaluate the diagnostic and therapeutic utility of molecular biomarkers derived from blood and endolymphatic fluid in MD. DATA SOURCES: A comprehensive literature search was conducted using OVID Medline, Ovid EMBASE, EBSCO CINAHL, Web of Science Core Collection, ProQuest Dissertations, and the Cochrane Library, utilizing controlled vocabulary (MeSH/Emtree terms) and related keywords. REVIEW METHODS: Following PRISMA guidelines, 2 independent reviewers performed the study screening, data extraction, and bias assessment of the isolated studies. RESULTS: The 21 studies consisted of case-control (71.4%), randomized trials or reviews (14.4%), cohort (9.5%), and case series (4.8%). Isolated biomarkers were classified as structural (24%), regulatory (24%), immunologic/oxidative stress (38%), and miscellaneous (14%). Structural proteins, such as otolin-1, otoconin-90, demonstrated potential in distinguishing MD from other vestibular disorders. Regulatory biomarkers (aquaporin-2, vasopressin-related peptides) were linked to fluid abnormalities. Inflammatory cytokines (TNF-α, IL-6, and IL-1β) and oxidative stress markers (4-HNE) highlighted disease heterogeneity. Additional findings such as unique vitamin D, estradiol, and altered metabolomic profiles suggested hormonal and metabolic changes. CONCLUSION: Molecular biomarkers offer critical insights into MD pathogenesis as well as potential diagnostic and therapeutic advancements. However, methodological variability and lack of replication necessitate standardized validation before formal clinical application.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Kamran H, Jimoh Z, Issa T, et al. Molecular Biomarkers in Meniere's Disease: A Scoping Review of Current Evidence. Otolaryngol Head Neck Surg. 2026. PMID: 42606302. doi:10.1002/ohn.70401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。